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Cell-based therapy continues to grow as a new field to explore investigational treatments for 
stroke. Leaders from academia and industry convened an inaugural meeting in 2007 with 
members of the National Institutes of Health and Food and Drug Administration (FDA) to 
generate consensus-based guidelines on the development of cell therapies for stroke, entitled 
“Stem Cells as an Emerging Paradigm in Stroke” (STEPS).1 These guidelines focused on 
preclinical studies that are considered important as part of a development program to support 
clinical testing of cell therapies. The STEPS meeting also provided recommendations on the 
conduct of early-stage clinical trials. Given the rapid advances in the field, a second meeting 
was held in 2009 to update and expand these guidelines, which were published as STEPS 2.2 
In December 2011, investigators in academia, industry leaders, and members of the National 
Institutes of Health and FDA gathered at a third meeting, STEPS 3, to discuss emerging data 
on the mechanisms of action of cell therapy, the barriers to successful translation from 
animal models to patients, and the design of current clinical trials for acute and chronic 
stroke. Since the prior STEPS meeting, there are now several active cell therapy platforms 
for stroke and other neurological disorders, in stages that range from preclinical to clinical 
trials, and with sponsors that include industry, the National Institutes of Health, and the 
California Institute of Regenerative Medicine. As the field continues to progress and as pilot 
clinical studies are starting to show safety for some cell types, it has become necessary to 
formulate a new set of guidelines that address topics not covered in prior STEPS 
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publications. Specifically, the current document reflects a compilation of recommendations 
that focus on more advanced stages of clinical testing, as well as the testing of cell therapies 
in a broader stroke population that includes chronic stroke.
New Developments in the Field
Cell-based therapies for stroke began as a field during the 1990s, in parallel with studies of 
tissue transplantation to treat neurodegenerative disorders. Initial pilot stroke studies 
examined the safety of intracranial delivery of neural cells in patients with stable, chronic 
basal ganglia infarcts. 3,4 Since the publication of those original reports, hundreds of studies 
in animal stroke models for more than a decade have shown that various types of cells 
including those from non-neural sources, such as bone marrow and umbilical cord, can 
enhance recovery. Rather than cell replacement, the mechanisms of action principally 
involve stimulation of endogenous repair processes, promotion of brain plasticity and 
synaptic reorganization, immunomodulation, and reduction in secondary injury. 5,6 Some 
types of cell therapies, when administered systemically, may not even enter the central 
nervous system in substantial quantities and instead may indirectly promote stroke recovery 
by acting on peripheral organs.7
Phase I and II clinical studies in stroke are underway around the world, mainly testing 
safety, with a few trials also exploring signals of efficacy. The majority of clinical trials 
involve patients in the subacute stages of stroke, although a handful of studies are testing 
cell-based therapies in patients with chronic stroke. Both autologous approaches, for 
example, using a patient's own bone marrow,8,9 and allogeneic approaches, many of which 
are manufactured by industry, are under investigation. Nearly all cell therapy platforms in 
registered clinical trials are using non-neural cells. Even before their completion, these trials 
have raised important questions that were addressed in workshops during the STEPS 3 
meeting. The workshops focused on phase II/III trials of cell therapy (Table 1) and 
establishing guidelines for chronic stroke (Table 2). These workshops generated 6 groups of 
recommendations:
Phase II/III Trials: Patient Selection
In an early-stage clinical trial in which the primary aim is to assess safety, excluding patients 
with certain comorbidities (such as renal or hepatic disease) might be helpful to minimize 
the frequency of adverse events that are more reflective of a patient's chronic diseases rather 
than effects of the therapy under study. However, use of such an approach in later-stage trials 
can slow recruitment rates. Use of restrictive inclusion/exclusion criteria is a trade-off 
between conducting a cleaner and a faster study. A major question is how to balance these 
competing goals and assure the broadest range of approved usage. One key consideration is 
to structure entry criteria with respect to properties of the cell therapy of interest, for 
example, patients with renal dysfunction or a history of neoplasia might be excluded when 
this is a particular concern for the therapy being evaluated. We favor identifying adverse 
interactions in preclinical studies, which echoes recommendations for the development of 
acute stroke therapies.10 Another key issue is to select patients with respect to the natural 
history of the stroke syndrome because the null hypothesis in a cell therapy trial is that there 
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is no difference compared with natural recovery. Most patients exhibit a limited spontaneous 
recovery, but a subset of patients with stroke remain severely impaired.11 The expected 
recovery level of a given patient with stroke may not be predicted with certainty at the time 
when an acute or subacute cell therapy trial is initiated. Potential exclusionary criteria might 
introduce a bias in the natural history of stroke recovery by selecting for a patient population 
with an overall distinct level of recovery. This discussion illustrates that a greater 
understanding of the natural history of stroke recovery is urgently needed, not just for the 
design of phase II/III cell therapy studies, but also to inform trials of all therapeutic 
modalities that have the goal of enhancing stroke recovery.
Study power is reduced when enrolling patients who have a particularly low chance of 
responding to the cell therapy under study.12 Several methods show promise for their ability 
to pro-spectively distinguish responders from nonresponders, 13 for example, by assessing 
the integrity of key white matter tracts, the functional state of the brain, neurophysiological 
status, and possibly genetic features. Such investigations might be considered as entry/
exclusion criteria, as evidence for their use accrues. At the same time, determining whether 
such studies can be completed within the optimal therapeutic time window for a particular 
cell therapy will also be important. Alternatively, selecting patients with no predicted natural 
recovery may enhance the power of the study to detect an effect. Stratified randomization 
may allow testing of cell therapies across a range of predicted natural responses based on 
key physiological parameters.
Patient selection is also intimately connected with study end points. As the focus of clinical 
trials advances from safety to efficacy, study hypotheses will focus on demonstrating 
significant behavioral and functional gains. Patient enrollment must be appropriate for the 
end points used to assess these hypotheses. For example, it will be necessary to enroll 
patients who have deficits in the domains that will be evaluated as end points—a study 
focused on improving arm motor function needs to ensure that enrollees have arm motor 
deficits in the target range at baseline. This issue is also connected with the need to align 
outcome measures in clinical trials with those used in preclinical studies.
Phase II/III: Time Window
The choice of the time window for patient selection should be informed by preclinical 
studies. Early-phase safety studies on cell therapies might recruit patients in the subacute to 
chronic window, where patients have stable neurological deficits and the targeted cell 
therapy–mediated mechanisms of action might be of secondary importance. However, later-
phase efficacy studies should maximally align to the extent possible the treatment time 
window with the intended pathophysiological targets defined from preclinical supporting 
data. This issue is complicated by the fact that patients with more severe strokes can 
deteriorate in the acute stage,8 making it difficult to separate adverse effects of treatment 
from the natural history of severe strokes. On the contrary, patients with milder strokes or 
who have few medical complications are often discharged to an acute rehabilitation facility 
or home early after stroke onset to reduce length of stay and hospital costs, making it 
difficult to treat and monitor study patients in a standardized environment.
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The pre-eminent issue for outcome measures is the need to ensure that the end points satisfy 
regulatory concerns. Global end points have been the main focus of stroke trials to date, for 
example, in the approval of tissue plasminogen activator. These global end points are based 
on assessments of disability, rather than impairment, such as the modified Rankin Scale, the 
National Institutes of Health Stroke Scale, or the Barthell Index. However, evaluation of 
restorative therapies such as stem cells would benefit from the use of domain-specific end 
points, which are sensitive to the differences in recovery across different neural systems14 
and more directly relate to the behavioral dysfunction of the affected brain system. These 
end points include specific measures of motor function such as the Fugyl Meyer, Action 
Arm Research Test, and walking speed, which have been validated for assessment of stroke 
outcomes and used in recent large-scale clinical trials.15–18 The FDA has indicated that 
domain-specific end points are acceptable as primary outcome measures as long as global 
end points are retained as secondary outcomes and furthermore that the proposed domain-
specific end point needs to be validated. The safety profile of a therapy might also influence 
the degree to which an end point is deemed to be acceptable. Of course, the priorities for 
selecting trial end points vary across phases of study, for example, safety versus efficacy. 
Choosing selective end points is desirable in phase II to detect a signal of efficacy at such a 
vulnerable phase of development. Indeed, the choice of end points can become a deciding 
factor in the decision to continue or terminate a cell therapy platform. The issue of end point 
selection is intertwined with selecting study entry criteria because the cohort enrolled must 
be appropriate for demonstrating an effect of the cell therapy under study.
Biomarkers of Activity
As was stressed in the prior STEPS 2 publication, 2 there is a great need for markers to 
gauge the biological activity of a cell therapy. Phase II trials would likely benefit from the 
inclusion of mechanistic end points. The selection of the route of administration, type of 
concomitant rehabilitation, and outcome measures might depend, at least in part, on the 
intended mechanism(s) of action of the cell therapy. At the present time, however, there are 
no validated biological markers of stroke recovery, although there is ongoing work 
suggesting potential substrates on neuroimaging that correlate with or even predict good 
outcomes.19 These substrates include white matter integrity using diffusion tensor imaging, 
laterality index using functional MRI, resting state connectivity, motor-evoked potential 
using transcranial magnetic stimulation, metabolites using magnetic resonance spectroscopy, 
and structural volumetric assessments of both gray and white matter. A biomarker stroke 
recovery consortium would help to address this void in the field.
Concomitant Rehabilitation Therapy
A body of research indicates that restorative therapies are maximally effective at improving 
behavioral outcomes if introduced in parallel with behavioral reinforcement such as 
rehabilitation therapy.20 There is evidence in animals with the use of enriched environments 
or specific behavioral paradigms of limb use that rehabilitation might be a confounding 
factor in assessing the efficacy of a neural therapy because this enrichment will directly 
impact the recovery process independently from the therapy and also in possible synergy 
Savitz et al. Page 4













with the therapy.21–23 Furthermore, there is evidence that rehabilitation of patients with 
stroke has a dose effect, such that the more rehabilitative activity is received, the greater the 
outcome.24 Therefore, as a clinical trial advances to phase II, discussing what form of 
concomitant rehabilitation the patients will receive becomes an important consideration. The 
importance of rehabilitation will also depend on the intended mechanism of action of a cell 
therapy. At a minimum, we think that rehabilitation is a variable that must be addressed by 
the time a cell therapy moves to phase II and will need to be incorporated and specified in 
detail in any phase III trial. Because patients often pursue rehabilitation therapy outside of 
study procedures, 25 measuring the total rehabilitation therapy exposure during clinical trial 
participation may be important.
Several key questions remain: which type of and how much rehabilitation? There is limited 
consensus regarding standard of care for rehabilitation. What modalities will be delivered, 
how, and when? As the content of rehabilitation differs across patients, expectations and 
possibly end points can also differ. Specifying the type of rehabilitation also affects patient 
selection. Appropriate lessons can be gleaned from trials such as the Locomotor Experience 
Applied Post-Stroke (LEAPS), 17 in which the patterns of neurorehabilitative activity were 
prespecified across treatment arms. Specifying rehabilitation content also has implications 
for the design of late-phase studies, the regulatory pathways, and ultimately labeling. Does a 
particular cell therapy require rehabilitation to maximize effect or perhaps does the 
combination lead to synergy? If a cell therapy plus rehabilitation is found to be superior to 
rehabilitation alone or the agent alone, such a result might lead to labeling as a combination 
therapy. This notion underscores the value of consulting with regulatory agencies about the 
role and importance of rehabilitation in any phase III trial, and we recommend specifically 
for the FDA, End of Phase 2 meeting.
Including some form of rehabilitation into a stem cell intervention, even at the phase II, 
might improve patient recruitment and interest in a trial in which one arm receives placebo 
and both arms receive rehabilitation. However, making rehabilitation a requirement for trial 
participation can be a source of enrollment bias. To what extent might enrolling motivated 
patients influence end points? No matter the time window, the influence of rehabilitation 
needs to be taken into account because early rehabilitation within the first few days after 
stroke has already been shown to be safe26 and the efficacy of early mobilization is now 
being studied in the A Very Early Rehabilitation Trial for Stroke (AVERT).
In earlier stages of testing, some studies are simply using a questionnaire to capture the 
quantity and quality of rehabilitation that patients are receiving. These questionnaires need 
to be validated to define the type, quantity, content, and duration of rehabilitation therapy a 
patient undergoes after a stroke.
Chronic Stroke
The majority of ongoing cell therapy clinical trials involving a systemic delivery route are 
focusing on the acute to subacute stages of stroke given the greater volume of preclinical 
data in this time period. The mechanisms of action of several types of cell therapies involve 
stimulation of active repair mechanisms that become operational in the acute to subacute 
time frame. In addition, some cell therapies modulate the postischemic inflammatory 
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response in the first few days after stroke. Much less is known about whether cell therapies 
may improve outcome in chronic stroke. There are a few types of cell therapies in which 
results from multiple publications have demonstrated improved outcomes when 
administered at 1 month after stroke,27–30 a time period in rodents in which stroke enters 
into a more chronic phase. Few published reports exist on the effects of other cell types in 
preclinical studies at time points of a month or later, which is noteworthy considering that 
the first FDA-approved clinical trial of cell therapy for stroke was based on a chronic stroke 
model.31 This issue may partly be explained by the lack of preclinical behavioral tests that 
are sensitive to detect deficits at later time points and the expense of long-term animal 
maintenance costs.
In contrast to the acute–subacute studies, all prior and existing clinical trials that involve 
stereotactic intraparenchymal cerebral injection of cell therapies are enrolling patients ≥6 
months after stroke onset.3,4 Some of these trials have unpublished preclinical studies testing 
cell therapies at later time points. However, the major rationale for treating ≥6 months after 
stroke is to study patients who have already plateaued in their recovery despite maximal 
physical and occupational therapy. Under this circumstance, any clinical change might be 
attributed to the cell therapy, although even in chronic stroke, some patients can achieve 
gains with structured physical or occupational therapies. Any cell therapy trial must be 
cognizant of the other therapeutic/ rehabilitative activities of enrolled patients.
At the present time, preclinical models of chronic stroke are limited. There is an insufficient 
understanding of the science of chronic stroke to provide definitive guidelines regarding 
efficacy and appropriate patient selection for cell therapy in chronic stroke. We offer the 
following points and recommendations for future development and testing of cell therapy in 
this setting.
Recommendations for Future Stem Cell Research in Chronic Stroke
1. Cell therapies that work in acute or subacute stroke may not be efficacious in 
chronic stroke. Conversely, cell therapies that work in chronic stroke might not 
be efficacious in acute or subacute stroke.
2. A definition for chronic stroke in humans is needed. We propose to define a 
chronic stroke as ≥6 months after onset, with no change in deficits for ≥2 
months.
3. Testing of a cell therapy for chronic stroke should first be studied in animal 
models (≥1 month after stroke). Animals should have stable deficits by this time 
point that can be measured and quantified to test a purported new therapy. A 
battery of behavioral tests should be included in the characterization of the model 
and for the purposes of post-translational clinical outcome. Variation of 
chronicity among different animal models should be considered. As 
recommended in STEPS 1 and 2, 1,2 multiple models should be investigated in 
different laboratories. Aged animals, both sexes, and animals with comorbidities 
should also be considered. Dosing should be consistent with future human 
applications and scaled appropriately. Primates and other large animal models 
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are optional, may not be cost effective, and best reserved for questions that 
cannot be adequately answered in rodent models.
4. Any development program using a cell therapy for chronic stroke should explore 
and define mechanisms of action in animal models. Any relevant mechanism 
should be incorporated to the extent possible as an appropriate measure in the 
design of a clinical trial.
5. For clinical testing, we must be aware of any relevant comorbidities for all 
possible patients, including pre-existing neurological disorders and cancers. The 
recovery process will be different if, for example, patients with previous strokes 
or dementias are included in clinical trials.
6. Use of imaging in clinical trials is strongly encouraged to provide as much 
information as possible to assess vascular/structural lesions, infarct size, cell 
viability, location, the success and safety of implantation, and inflammation. 
Imaging should also be used to monitor safety and recovery and, when possible, 
to investigate mechanisms of action and provide information on surrogate 
markers of treatment effect. Imaging measures might also be useful to help 
stratify patients at baseline.
7. The safest and most effective route of cell delivery should be defined using 
preclinical studies.
8. Adjuvant therapies: The content of rehabilitation should be evidence based, 
standardized insofar as possible, and monitored. If enrolled in a cell therapy trial, 
participation in other types of investigational therapies should be discouraged. 
We expect that multimodal approaches will be tested in the future, but clinical 
trials should take into account the additional confounding variables and consider 
multiarm studies.
9. For any end point in a clinical trial, a clinical baseline before treatment and 
assessment of stability is important. We recommend domain-specific end points 
assessing the recovery of sensory, motor, visual, and cognitive functions using 
validated measures.
10. Biomarkers when available should be incorporated in any clinical trial. Obtaining 
blood or tissue is important to monitor rejection for any allogeneic study and 
track any biochemical or imaging data indicative of restorative events.
11. Safety parameters should be followed in some capacity for ≥1 year, with precise 
study duration for specific stem cell therapies based on preclinical data and 
discussions with regulatory agencies. Data Safety Monitoring Boards are 
essential for tracking serious adverse events. We recommend engaging regulatory 
agencies during all appropriate time points of the clinical trial.
12. Safety trials may be undertaken with all patients receiving active treatment. Early 
efficacy trials of cell therapies in chronic stroke face the need to establish a 
plausible biological response with a minimum number of subjects within a short 
time frame. Assessing treatment effects by change over time in individual 
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patients with fixed deficits and well-defined natural history without the use of 
placebo controls may have use in early phase 2 studies in which a clear go/no-go 
decision is needed. However, a true treatment effect can only be attributed to the 
study intervention where appropriate control groups are included. Although sham 
surgeries for stereotactic delivery are invasive, there are reports of patients with 
chronic stroke reporting immediate improvement after intracranial injection of 
neural cells.4 The inclusion of sham controls in later-phase efficacy trials is 
optimal to distinguish potential effects attributed to placebo, surgery, or the cell 
therapy, but the risks of sham procedures in the target clinical population must be 
balanced against scientific desirability. In addition, lack of patient acceptability 
of sham procedures may compromise recruitment32 and itself introduce bias. 
Alternative methods to address the issues raised by sham surgical controls such 
as crossover trials that permit control patients to receive the study intervention at 
a later time point or a stepped wedge design in which the study intervention is 
rolled out sequentially to all participants during succeeding periods of time 
should be considered as alternatives.
13. The application of neural cells to replace lost brain tissue and reestablish lost 
connections after a stroke is an important goal but will require extensive 
advances in basic science before implementation in clinical studies.33 A range of 
bioengineering devices including scaffolds and hydrogels are being developed 
and studied for the purposes of remodeling the brain after stroke and other 
injuries.
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Table 1
Suggestions for Phase II/III Efficacy Trials
1 Structure entry criteria with respect to properties of the cell therapy of interest, the natural history of the stroke syndrome, and 
study end points to assess hypotheses.
2 The choice of the time window for patient selection should be based on the basis of preclinical studies. Later-phase efficacy 
studies should maximally align the treatment time window with the intended pathophysiological targets.
3 Evaluation of restorative therapies such as stem cells would benefit from the use of domain-specific end points, which are 
sensitive to the differences in recovery across different neural systems. These end points should be chosen in phase II to detect a 
signal of efficacy at such a vulnerable phase of development.
4 At a minimum, rehabilitation is a variable that must be addressed by the time a cell therapy moves to phase II and will need to be 
incorporated and specified in detail in any phase III trial.
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Table 2
Suggestions for Testing Cell Therapies in Chronic Stroke
1 Testing of a cell therapy for chronic stroke should first be studied in animal models (≥1 mo after stroke).
2 Any development program using a cell therapy for chronic stroke should investigate and define mechanisms of action in animal 
models.
3 Comorbidities need to be taken into consideration when planning a clinical trial, and preclinical studies should be performed, if 
possible, to evaluate the effects of cell therapy on stroke with comorbidities.
4 Imaging in clinical trials is strongly encouraged to provide as much information as possible to assess safety, vascular/structural 
lesions, infarct size, cell viability, location, and inflammation, and intended mechanisms of action when possible.
5 The safest and most effective route of cell delivery should be defined using preclinical studies.
6 The content of rehabilitation should be standardized insofar as possible and monitored.
7 We recommend domain-specific end points assessing the recovery of sensory, motor, visual, and cognitive functions using 
validated measures.
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